EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs

Anna Mestre Borras iD, Hanna Mehari iD, Stefan Ståhl, John Löfblom iD

Protein Engineering, Design and Selection · 2026

DOI: 10.1093/protein/gzag010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, 2026. Verfasst von Anna Mestre Borras und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, SE-106 91, S…. Hauptthemen laut MEDLINE: Prodrugs, Nivolumab, Protein Engineering, Recombinant Fusion Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Swedish Research Council, Knut and Alice Wallenberg Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody prodrugs provide a strategy to reduce systemic toxicity by masking therapeutic antibodies until activation in specific physiological environments. Nivolumab, an anti-PD-1 checkpoint inhibitor used in cancer immunotherapy, can cause immune-related adverse events. As a first step toward a prodrug version of nivolumab, we screened an Escherichia coli affibody library using MACS and FACS, identifying affibodies that effectively mask its PD-1-binding regions. Deep sequencing revealed an unexpected enrichment of proline-rich variants, possibly mimicking a PD-1 loop. AlphaFold modeling suggested that these affibodies form interactions with nivolumab despite low alpha-helical content. Biosensor assays confirmed effective masking in a nivolumab prodrug format, with PD-1 binding restored upon proteolytic cleavage. These findings support further exploration of PD-1–mimicking affibodies as masking domains, advancing the development of more selective nivolumab prodrugs with improved safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNivolumabProtein EngineeringRecombinant Fusion ProteinsEscherichia coliHumansProgrammed Cell Death 1 ReceptorModels, MolecularProtein Domains

Stichwörter der Autor:innen

PD-1affibody moleculebacterial displayconditional activationdirected evolutionnivolumabprodrug

Substanzen

ProdrugsNivolumabProgrammed Cell Death 1 ReceptorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, SE-106 91, Stockholm, Sweden.

ORCID-Profile: Anna Mestre Borras, Hanna Mehari, John Löfblom

Förderung

  • Swedish Cancer Society
  • Swedish Research Council
  • Knut and Alice Wallenberg Foundation
  • Wallenberg Center for Protein Research - WCPR
  • Hjärnfonden
  • Swedish Agency for Innovation VINNOVA
  • CellNova center

Zitieren

APA

Mestre Borras, A., Mehari, H., Ståhl, S., & Löfblom, J. (2026). Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs. Protein Engineering, Design and Selection. https://doi.org/10.1093/protein/gzag010

Vancouver

Mestre Borras A, Mehari H, Ståhl S, Löfblom J. Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs. Protein Engineering, Design and Selection. 2026. doi:10.1093/protein/gzag010

BibTeX
@article{MestreBorras2026,
  author = {Mestre Borras, Anna and Mehari, Hanna and Ståhl, Stefan and Löfblom, John},
  title = {Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs},
  journal = {Protein Engineering, Design and Selection},
  year = {2026},
  doi = {10.1093/protein/gzag010}
}
Kostenlos starten →